BioMed X Launches Drug Delivery Research Project with Janssen
The project is aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.
BioMed X, a German independent research institute, announced on Jan. 26, 2021 that it is launching a research project with Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.
“There are several techniques available to shield these macromolecules from the harsh conditions of the gastrointestinal tract, but little progress has been made to translocate complex macromolecules across the intestinal epithelial barrier into systemic circulation,” said Christian Tidona, founder and managing director of the BioMed X Institute, in a company press release. “This project has the potential to provide us with a novel delivery platform that enables the development of a new generation of oral immunotherapies.”
The companies are currently searching for early-career biomedical researchers interested in the field of drug delivery to head the project and plan on hiring one group leader, two postdoctoral researchers, and two research assistants, BioMed X said in the press release.
Source: BioMed X
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
